课题基金 / 基金详情

IGF::OT::IGF NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF ECD-IG PROTEIN

IGF::OT::IGF NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF ECD-IG PROTEIN
IGF::OT::IGF NIAID 临床前开发支持 - ECD-IG 蛋白的生产
批准号：
9334668
负责人：
THOMAS VANCOTT
金额：
$37.41万
依托单位：
ADVANCED BIOSCIENCE LABORATORIES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
项目状态：
已结题
起止时间：
2015-09-18 至 2022-12-31
来源：
https://reporter.nih.gov/project-details/9334668
关键词：
AIDS preventionContractsDataDevelopmentDocumentationGuidelinesHIV vaccineInvestigational DrugsInvestigational New Drug ApplicationInvestigator-Initiated ResearchModalityNational Institute of Allergy and Infectious DiseasePamphletsPhasePreclinical TestingProcessProductionProteinsProtocols documentationResearch PersonnelSafetyTestingauthorityflexibilityimmunogenicitymicrobicidepre-clinicalresearch clinical testingresearch study

项目摘要

项目成果

THOMAS VANCOTT的其他基金

相似基金

相关文献

中文摘要
翻译
该合同将为NIAID提供广泛而灵活的非传统，主动和以开发为导向的能力，为有前途的产品提供临床前开发，当这些产品从制药商发起的研究中出现时。这些能力将使NIAID能够更快、更有效地缩小开发和生产差距。活动将包括但不限于小规模生产、临床前试验和文件编制，以提交研究性新药（IND）进行I、II和III期临床试验。主要目的是开发eCD4 IG蛋白。
英文摘要
This contract will provide NIAID with a broad and flexible range of nontraditional, proactive and developmentally-oriented capabilities to provide preclinical development for promising products for when such products emerge from investigator-initiated research studies. These capabilities will allow NIAID to more rapidly and efficiently close development and production gaps. Activities will include but not limited to small-scale production, preclinical testing and documentation leading to Investigational New Drug (IND) submission for Phase I, II, and III clinical testing. The primary aim is for the development of an eCD4 IG Protein.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Essential Core Activities: NIAID Preclinical Development Support
NIAID Preclinical Development Support: Adjuvants for HIV-1 Vaccines
ESSENTIAL CORE ACTIVITIES, NIAID PRECLIN DEVELOPMENT SUPPORT
Essential Core Activities: NIAID Preclinical Development Support
海外基金